The Filing Desk

Avalo Therapeutics vs Inovio Pharmaceuticals

Avalo Therapeutics AVTX · Inovio Pharmaceuticals INO · Pharmaceuticals

Avalo Therapeutics reported revenue of $0 million in fiscal 2025, about the same as Inovio Pharmaceuticals' $0 million in fiscal 2025. Avalo Therapeutics' revenue fell 86.6% in its latest year, and Inovio Pharmaceuticals' fell 70.0%. Avalo Therapeutics had an operating margin of -123601.7%, against -132871.3% at Inovio Pharmaceuticals.

Side by side

Avalo TherapeuticsInovio Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth−86.6%−70.0%
Revenue growth a year, last 5 years−56.9%−57.7%
Gross margin——
Operating margin−123,601.7%−132,871.3%
Net margin−132,642.4%−130,000.0%
Free cash flow—−$89M
Free cash flow margin—−136,074.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count78.8%72.6%
Last close$6.75$1.71
P/E at the last close——
Insider trades, last 12 monthssold $8.3 million—
Piotroski F-score2 of 80 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Avalo TherapeuticsInovio Pharmaceuticals
Operating margin
Percent of revenue
Avalo TherapeuticsInovio Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Avalo TherapeuticsInovio Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Avalo Therapeutics and Inovio Pharmaceuticals pages.